EBRT Regimens Elicit 15-Year Prostate Cancer Survival Outcomes
More adverse factors occurred in those with intermediate-risk prostate cancer undergoing neoadjuvant androgen deprivation therapy than those who did not.
DESTINY-Breast06 Efficacy Surpasses SOC in HER2-Low/Ultralow Breast Cancer
Findings from DESTINY-Breast06 showed a PFS of 13.2 months for patients given T-DXd for HER2-low or ultralow breast cancer.
UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies
The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.
Anakinra Ineffective in Preventing CRS/ICANS After Liso-cel in LBCL
Anakinra prophylaxis did not significantly decrease the incidence or severity of CRS or ICANS in patients with LBCL treated with liso-cel.
Sotorasib Combo Has Positive PFS Impact in KRAS G12C-Mutated CRC
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Obe-Cel Is Effective in R/R B-ALL Patients with Low CAR-HT Risk
Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.
Tuspetinib Triplet Therapy Achieves Early Responses in AML
A total of 3 patients with AML treated with the lowest dose of tuspetinib at 40 mg completed the first cycle of treatment with no dose-limiting toxicities.
Talazoparib and Enzalutamide Improve Outcomes in Advanced Prostate Cancer
The TALAPRO-2 trial revealed promising survival data for patients with metastatic CRPC treated with talazoparib and enzalutamide.
Neoadjuvant Nivolumab Combo Boosts Pathologic Response in ER+ Breast Cancer
Data from the CheckMate 7FL trial may inform treatment decisions regarding preoperative immunotherapy for patients with breast cancer.
Highlighting Quality of Life Considerations for MZL Treatment
Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment.
INB-100 After HSCT Shows Enduring Efficacy in Complex Leukemias
Early INB-100 results showed the potential to achieve durable remissions and improve survival in patients with complex leukemias, particularly AML.
A Look at Upcoming Impactful Presentations at ASCO GU 2025
The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.
Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer
Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.
T-DXd Approval Appears Significant in HER2-Low/Ultralow Breast Cancer
Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range.
Creating a Collaborative Edge Through the MZL Workshop
Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.
FDA OKs Brentuximab Vedotin Combo in R/R Large B-Cell Lymphoma
Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.
Objective Data Highlight Substantial Benefits With Mirdametinib in NF1-PN
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Data Open The Door for Earlier Sotorasib/Panitumumab Use in KRAS G12C+ CRC
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Mirdametinib Approval Brings Tumor Shrinkage and QOL Advantages to NF1-PN
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
FDA Approves Mirdametinib in Adult/Pediatric NF1-PN
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.
FDA Accepts Linvoseltamab BLA for Review in R/R Multiple Myeloma
Efficacy results from the phase 1/2 LINKER-MM1 trial evaluating linvoseltamab in relapsed or refractory multiple myeloma support the decision.
Nodal Marginal Zone Lymphoma and Its Diagnostic Challenges
A pathologist discusses the challenges of diagnosing nodal MZL, including its lack of specific defining characteristics.
FDA Grants Fast Track Designation to Amezalpat Combination in HCC
Amezalpat plus atezolizumab and bevacizumab achieved a 6-month increase for OS compared with atezolizumab and bevacizumab alone in patients with HCC.
Improvements Over Chemo Yield Sotorasib Combo Approval in KRAS G12C+ CRC
Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.
Breast Cryoablation Inhibits Recurrence, Enhances Survival in Breast Cancer
Findings from the ICE3 trial revealed that no serious adverse effects were experienced related to the use of cryoablation in ipsilateral breast tumors.
Sotorasib Combo Approval is ‘Welcome Step’ in KRAS G12C+ CRC Care
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma
Hematologists gathered to discuss recent updates on bispecific antibodies surrounding patients with relapsed/refractory multiple myeloma.
Liso-cel Demonstrates Significant Responses in Relapsed/Refractory MZL
In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.
Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research
Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
